tetano
Editor, Senior Moderator
Medicina (Kaunas)
. 2021 Dec 27;58(1):37.
doi: 10.3390/medicina58010037.
De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor
Smaragdi Marinaki[SUP] 1 [/SUP], Kyriaki Kolovou[SUP] 1 [/SUP], George Liapis[SUP] 2 [/SUP], Chrysanthi Skalioti[SUP] 1 [/SUP], Stathis Tsiakas[SUP] 1 [/SUP], Ioannis Boletis[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 has developed as a pandemic. Immunization with the introduction of vaccines against COVID-19 seems be the only way to end this pandemic. We report on a case of a kidney donor, who developed minimal change disease (MCD) within 4 days post-vaccination with the SARS-CoV-2 BNT162b2 mRNA vaccine (Pfizer/BioNTech). She donated her kidney to her husband 4 years ago. After receiving the 1st vaccine dose, she presented with nephrotic syndrome, with complete remission 5 days later. She proceeded with the second dose of the BNT162b2 vaccine at the appointed time. Two days later, she presented with a relapse of full-blown nephrotic syndrome with preserved renal function. We performed an ultrasound-guided percutaneous kidney biopsy and the final diagnosis was consistent with minimal change disease. Oral prednisolone was promptly initiated at a dosage of 1 mg/kg daily and complete remission was achieved 10 days later. More data about this rare appearance of de novo glomerular diseases after SARS-CoV-2 vaccination are emerging and should be interpreted rigorously.
Keywords: COVID-19 vaccination; SARS-CoV-2 mRNA vaccines; de novo glomerulonephritis; kidney donor; minimal change disease.
. 2021 Dec 27;58(1):37.
doi: 10.3390/medicina58010037.
De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor
Smaragdi Marinaki[SUP] 1 [/SUP], Kyriaki Kolovou[SUP] 1 [/SUP], George Liapis[SUP] 2 [/SUP], Chrysanthi Skalioti[SUP] 1 [/SUP], Stathis Tsiakas[SUP] 1 [/SUP], Ioannis Boletis[SUP] 1 [/SUP]
Affiliations
- PMID: 35056345
- DOI: 10.3390/medicina58010037
Abstract
Coronavirus disease 2019 has developed as a pandemic. Immunization with the introduction of vaccines against COVID-19 seems be the only way to end this pandemic. We report on a case of a kidney donor, who developed minimal change disease (MCD) within 4 days post-vaccination with the SARS-CoV-2 BNT162b2 mRNA vaccine (Pfizer/BioNTech). She donated her kidney to her husband 4 years ago. After receiving the 1st vaccine dose, she presented with nephrotic syndrome, with complete remission 5 days later. She proceeded with the second dose of the BNT162b2 vaccine at the appointed time. Two days later, she presented with a relapse of full-blown nephrotic syndrome with preserved renal function. We performed an ultrasound-guided percutaneous kidney biopsy and the final diagnosis was consistent with minimal change disease. Oral prednisolone was promptly initiated at a dosage of 1 mg/kg daily and complete remission was achieved 10 days later. More data about this rare appearance of de novo glomerular diseases after SARS-CoV-2 vaccination are emerging and should be interpreted rigorously.
Keywords: COVID-19 vaccination; SARS-CoV-2 mRNA vaccines; de novo glomerulonephritis; kidney donor; minimal change disease.